VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EBMT 2021 | Challenges of CAR-T bridging to allo-SCT

Livio Pagano • 8 Mar 2021

Livio Pagano, MD, Catholic University of Sacred Heart, Rome, Italy, discusses challenges associated with using chimeric antigen receptor T-cell (CAR-T) therapy as a bridging therapy to allogeneic stem cell transplantation (allo-SCT), outlining the increased risk of fungal infection. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.

Disclosures

Prof. Livio Pagano, MD, discloses connections to Jazz Pharmaceuticals, Janssen, Novartis, Gilead, Menarini, Cidara Therapeutics, Stemline, Pfizer and MSD.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter